An interventional study of NucleoCapture device in Sepsis and Sepsis-associated AKI, sponsored by Santersus AG. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-06.
Sponsored by Santersus AG · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Sepsis with a site in Russian Federation — 2 open to participants now, 2 under way, none of them phase 3. Sepsis · Russian Federation.
Among the 16 studies in Sepsis with a site in Russian Federation, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 4 that started in 2021, is one of 6 with no phase, and was the 8th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →2 of the 16 studies in Sepsis with a site in Russian Federation are open now. Recruiting first, the newest first:
Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology · Sites in Russian Federation
Ages 18+
Petrovsky National Research Centre of Surgery · Sites in Russian Federation
Ages 18–80
A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 78 across the 11 interventional studies, 66 across the 4 observational. Of the 12 that completed or were terminated, 2 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 16 have an industry lead sponsor. The 10 most frequent:
Santersus AG is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Santersus AG has 2 studies filed under Sepsis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies in Sepsis with a site in Russian Federation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open non-randomized controlled single center study investigates to what extent the removal of circulating Neutrophil Extracellular Traps (NETs) from blood by NucleoCapture device has a positive effect on the treatment of patients with sepsis and sepsis-associated AKI (SA-AKI).
The term "sepsis" refers to a clinical syndrome in which a dysregulation of the host's inflammatory reaction to infection leads to a life-threatening of organ dysfunctions. Sepsis and septic shock are major causes of death in intensive care units worldwide. Sepsis remains the most important cause of AKI in the intensive care unit (ICU) with 15%-20% of patients with sepsis-associated AKI (SA-AKI) prescribed RRT . In addition to association with short term mortality, AKI is also linked to the later development of CKD, ESRD, and long-term increased risk of death
NETosis is a unique form of neutrophil cell death that is characterized by the release of neutrophil extracellular traps (NETs) composed of DNA web-like structures decorated with highly cytotoxic protein components. Release of NETs leads to bystander tissue damage (including the kidneys) and drives a fatal course of disease in sepsis patients.
The plasmapheresis is a medical procedure, where pathogenic components are being removed from the blood by adsorbers outside the body in an extracorporeal circulation. For removal of the pathogenic substances the plasma is separated from the blood to pass the adsorber. The purified plasma is merged with the solid blood components thereafter and returned to the patient. The NucleoCapture device provide highly selective removal of neutrophil extracellular traps from human blood during plasmapheresis procedure.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm.
Device: NucleoCapture device
Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
Also known as: NucleoCapture selective DNA adsorber
Incidence of acute kidney injury (AKI)
Incidence of acute kidney injury (AKI) in accordance with Kidney Disease Improving Global Outcomes (KDIGO) definitions for AKI
Time frame: from [start of treatment] through 28 days after
Severity of acute kidney injury (AKI)
Severity of acute kidney injury (AKI) in accordance with KDIGO definitions for AKI
Time frame: from [start of treatment] through 28 days after
Rate of AKI transition to the more severe stage (for patients with AKI at baseline).
Rate of worsening of acute kidney injury (AKI) in accordance with KDIGO AKI classification (Changing stages from 1 to 2, from 2 to 3).
Time frame: from [start of treatment] through 28 days after
Serum creatinine change over time
Change of creatinine in serum over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
Serum urea change over time
Change of urea in serum over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
Urine output change
Change of urine output over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
All-cause mortality
Mortality for any reasons for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
SOFA scores change
Change in SOFA scores over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
qSOFA scores change
Change in qSOFA scores over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
Blood level of neutrophil extracellular traps (NETs) change over time
Change of NETs in blood over time for each patient and in average in group
Time frame: from [start of treatment] through 28 days after
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jan 2021 to primary completion in Oct 2021, 8 months.
Of 326 interventional studies with no phase under Sepsis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.